Operational highlights and financial results for the period ended march 31, 2021

New york, june 02, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended march 31, 2021.
MESO Ratings Summary
MESO Quant Ranking